Transplant drug helpful for patients with progressive liver condition

New research indicates that mycophenolate mofetil, a drug that is usually used to prevent rejection after kidney, heart or liver transplant, seems safe and effective in treating autoimmune hepatitis (AIH), a serious chronic liver disease that mainly affects women.

Treatment for AIH is usually based on steroids, which can have very serious side effects when taken long term either alone or in combination with the immunosuppressive drug azathioprine. In this latest real-world study, nearly 94% of patients had an initial complete response to mostly within 3 months of treatment. A total of 78 of 109 patients (72%) had a complete response on-treatment, and 61 of 78 (78%) maintained remission off steroids. Most importantly, mycophenolate mofetil as front-line treatment for AIH not only accomplished high rates of on-treatment response, but also showed the highest rates of maintenance of complete remission after complete drug withdrawal (75% of patients) ever published, for a median of 2 years.

"As relapse after drug withdrawal in AIH patients is almost universal with conventional therapy, mycophenolate mofetil seems a reasonable, safe, and important alternative first-line treatment of AIH that should seriously and urgently be considered in the future," said Dr. George Dalekos, senior author of the Alimentary Pharmacology & Therapeutics study.


Explore further

Alternative treatment for preventing relapse of certain type of vasculitis appears less effective

More information: K. Zachou et al. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis, Alimentary Pharmacology & Therapeutics (2016). DOI: 10.1111/apt.13584
Provided by Wiley
Citation: Transplant drug helpful for patients with progressive liver condition (2016, March 21) retrieved 13 April 2021 from https://medicalxpress.com/news/2016-03-transplant-drug-patients-liver-condition.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments